Frontiers in Oncology (Jan 2022)
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
Abstract
No abstracts available.Keywords
Frontiers in Oncology (Jan 2022)